Dongwha Pharm.Co.Ltd (000020) - Total Assets

Latest as of December 2025: ₩642.17 Billion KRW ≈ $435.19 Million USD

Based on the latest financial reports, Dongwha Pharm.Co.Ltd (000020) holds total assets worth ₩642.17 Billion KRW (≈ $435.19 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 000020 net asset value for net asset value and shareholders' equity analysis.

Dongwha Pharm.Co.Ltd - Total Assets Trend (2011–2025)

This chart illustrates how Dongwha Pharm.Co.Ltd's total assets have evolved over time, based on quarterly financial data.

Dongwha Pharm.Co.Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Dongwha Pharm.Co.Ltd's total assets of ₩642.17 Billion consist of 33.9% current assets and 66.1% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 2.1%
Accounts Receivable ₩83.01 Billion 12.9%
Inventory ₩97.87 Billion 15.2%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩57.17 Billion 8.9%
Goodwill ₩24.93 Billion 3.9%

Asset Composition Trend (2011–2025)

This chart illustrates how Dongwha Pharm.Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dongwha Pharm.Co.Ltd market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Dongwha Pharm.Co.Ltd's current assets represent 33.9% of total assets in 2025, a decrease from 39.0% in 2011.
  • Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 10.4% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 1.0% in 2011.
  • Asset Diversification: The largest asset category is inventory at 15.2% of total assets.

Dongwha Pharm.Co.Ltd Competitors by Total Assets

Key competitors of Dongwha Pharm.Co.Ltd based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Dongwha Pharm.Co.Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.07 1.77 3.39
Quick Ratio 0.59 1.11 2.78
Cash Ratio 0.00 0.00 0.00
Working Capital ₩14.79 Billion ₩103.80 Billion ₩159.84 Billion

Dongwha Pharm.Co.Ltd - Advanced Valuation Insights

This section examines the relationship between Dongwha Pharm.Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.43
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 3.6%
Total Assets ₩642.17 Billion
Market Capitalization $113.83 Million USD

Valuation Analysis

Below Book Valuation: The market values Dongwha Pharm.Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Dongwha Pharm.Co.Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Dongwha Pharm.Co.Ltd (2011–2025)

The table below shows the annual total assets of Dongwha Pharm.Co.Ltd from 2011 to 2025.

Year Total Assets Change
2025-12-31 ₩642.17 Billion
≈ $435.19 Million
+3.64%
2024-12-31 ₩619.63 Billion
≈ $419.92 Million
+9.68%
2023-12-31 ₩564.97 Billion
≈ $382.87 Million
+22.52%
2022-12-31 ₩461.14 Billion
≈ $312.51 Million
+2.98%
2021-12-31 ₩447.80 Billion
≈ $303.47 Million
+3.23%
2020-12-31 ₩433.81 Billion
≈ $293.99 Million
+15.37%
2019-12-31 ₩376.03 Billion
≈ $254.83 Million
+1.47%
2018-12-31 ₩370.60 Billion
≈ $251.15 Million
+0.92%
2017-12-31 ₩367.23 Billion
≈ $248.86 Million
+13.13%
2016-12-31 ₩324.60 Billion
≈ $219.98 Million
+2.34%
2015-12-31 ₩317.19 Billion
≈ $214.95 Million
+1.31%
2014-12-31 ₩313.07 Billion
≈ $212.17 Million
-0.98%
2013-12-31 ₩316.17 Billion
≈ $214.26 Million
-2.50%
2012-12-31 ₩324.28 Billion
≈ $219.76 Million
-4.46%
2011-12-31 ₩339.43 Billion
≈ $230.03 Million
--

About Dongwha Pharm.Co.Ltd

KO:000020 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$113.83 Million
₩167.97 Billion KRW
Market Cap Rank
#18692 Global
#968 in Korea
Share Price
₩6060.00
Change (1 day)
-0.49%
52-Week Range
₩5660.00 - ₩7060.00
All Time High
₩28554.43
About

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more